收藏切换
Cost-utility analysis of osimertinib for adjuvant treatment of epidermal grouth factor receptor mutation-positive non-small cell lung cancer
收藏切换
Jia LIU1, 2, Xiaoning HE1, 2, *
World Clinical Drug | 2022, 43(6) : 736 - 745
Less
收藏切换
World Clinical Drug | 2022, 43(6): 736-745
• Article •
Cost-utility analysis of osimertinib for adjuvant treatment of epidermal grouth factor receptor mutation-positive non-small cell lung cancer
Full
Jia LIU1, 2, Xiaoning HE1, 2, *
Affiliations
  • 1.School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
  • 2.Center for Social Science Survey and Data, Tianjin University, Tianjin 300072, China
Published: 2022-06-10 doi: 10.13683/j.wph.2022.06.015
Outline
收藏切换
Objective

To evaluate the cost-effectiveness of osimertinib for adjuvant treatment of patients with epidermal grouth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) after tumor resection from the perspective of Chinese healthcare system.

Methods

A 5-state Markov model with 1-month cycle was constructed, and the lifetime horizon was used. Data on patient baseline characteristics, transition probabilities, incidence of adverse events and health utilities were mainly derived from ADAURA study, supplemented by CancerLinQ database, FLAURA study and published literatures. Medical costs were derived from Chinese government documents, literature, and clinical expert surveys. Scenario analysis, one-way sensitivity analysis and probabilistic sensitivity analysis were conducted simultaneously.

Results

Base-case analysis results showed that for patients with EGFR mutation-positive NSCLC after tumor resection, the incremental cost of osimertinib compared with placebo was 25 395.25 yuan, the incremental quality adjusted life year (QALY) was 3.25, the incremental cost-effectiveness ratio (ICER) was 7 812.45 yuan/QALY, which was much lower than 1 times Chinese per capita GDP (72 447.00 yuan in 2020). Osimertinib has cost-effectiveness. Scenario analysis, one-way sensitivity analysis and probabilistic sensitivity analysis indicated that base-case analysis results were robust.

Conclusion

Under the threshold of 1-time Chinese per capita GDP, osimertinib was predicted to be the cost-effective treatment option compared with placebo for patients with EGFR mutation-positive NSCLC after tumor resection in China.

osimertinib  /  non-small cell lung cancer  /  adjuvant treatment  /  cost-utility analysis  /  Markov model
刘佳, 贺小宁. 奥希替尼用于表皮生长因子受体突变阳性非小细胞肺癌辅助治疗的成本-效用分析. 世界临床药物, 2022 , 43 (6) : 736 -745 . DOI: 10.13683/j.wph.2022.06.015
Jia LIU, Xiaoning HE. Cost-utility analysis of osimertinib for adjuvant treatment of epidermal grouth factor receptor mutation-positive non-small cell lung cancer[J]. World Clinical Drug, 2022 , 43 (6) : 736 -745 . DOI: 10.13683/j.wph.2022.06.015
Year 2022 volume 43 Issue 6
11
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.06.015
  • Receive Date:2022-01-17
  • Online Date:2026-11-19
  • Published:2022-06-10
Article Data
Affiliations
History
  • Received:2022-01-17
Affiliations
    1.School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
    2.Center for Social Science Survey and Data, Tianjin University, Tianjin 300072, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.06.015
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT